Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2025

Serna-Blasco Roberto, Mediavilla-Medel Pilar, Medina Karla, Sala María Ángeles, Aguiar David, Díaz-Serrano Asunción, Antoñanzas Mónica, Ocaña Julio, Mielgo Xabier, Fernández Inmaculada, López-Castro Rafael, Cobo Manuel, Martínez Mireia, Villa José Carlos, Rosado Petra, López Ana, Guirado María, Viteri Santiago, Rodríguez Delvys, García Florencia, Simón Soraya, Moreno María Ángeles, Catot Silvia, González Larriba José Luis, Salas Clara, Calvo Virginia, Romero Atocha, Provencio Mariano

Abstract excerpt

BACKGROUND: In Spain, next-generation sequencing (NGS) is currently available in a limited number of specialized centers and remains inaccessible to a significant proportion of patients. The ATLAS study aims to explore the tumor molecular profile beyond known EGFR mutations and ALK translocations using NGS on tumor biopsy samples. METHODS: Patients with EGFR-sensitizing mutations or ALK translocations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Cancer Diagnosis and Treatment

Share to Lung Cancer Treatments and Mutations

Source

Identifiers

PMID: 40300279
DOI: 10.1016/j.lungcan.2025.108550

Genes

ALK
EGFR
KRAS
MET
BRAF
RET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.PMID 40300279Read ↗

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.Semantic proximity Read ↗

Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesSemantic proximity Read ↗

Tumor molecular profiling of NSCLC patients using next generation sequencing.Semantic proximity Read ↗

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.Semantic proximity Read ↗

Genomic Landscape of NSCLC in the Republic of IrelandSemantic proximity Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.